Correlating immunity with protection for HPV infection (Q30051687)

19 April 2018

review article

1 reference

title

Correlating immunity with protection for HPV infection (English)

1 reference

19 April 2018

1

Ian Frazer

1 reference

19 April 2018

publication date

1 November 2007

1 reference

19 April 2018

International Journal of Infectious Diseases

published in

2 references

DOI.org query endpoint

https://doi.org/10.1016%2FS1201-9712%2807%2960016-2

25 May 2017

19 April 2018

volume

11 Suppl 2

1 reference

19 April 2018

page(s)

S10-6

1 reference

19 April 2018

Vaccination against human papillomavirus infection: a new paradigm in cervical cancer control

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Chapter 2: Natural history of anogenital human papillomavirus infection and neoplasia.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Prevention of cervical cancer through papillomavirus vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Antibodies against the human papillomavirus type 16 early proteins in human sera: correlation of anti-E7 reactivity with cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Cell-mediated immune response to human papillomavirus infection

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Skin Cancer and Warts in Immunosuppressed Renal Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Management of female genital warts with an analog of imiquimod 2% in cream: a randomized, double-blind, placebo-controlled study.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Synthesis and assembly of infectious bovine papillomavirus particles in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles.

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Papillomavirus L1 major capsid protein self-assembles into virus-like particles that are highly immunogenic

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Vaccination with yeast-expressed cottontail rabbit papillomavirus (CRPV) virus-like particles protects rabbits from CRPV-induced papilloma formation

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Human papillomavirus type 11 neutralization in the athymic mouse xenograft system: Correlation with virus-like particle IgG concentration

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Human Papillomavirus Type 11 (HPV‐11) Neutralizing Antibodies in the Serum and Genital Mucosal Secretions of African Green Monkeys Immunized with HPV‐11 Virus‐like Particles Expressed in Yeast

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Preventative and therapeutic vaccines for cervical cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil).

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS1201-9712%2807%2960016-2

7 January 2021

10.1016/S1201-9712(07)60016-2

Identifiers

DOI

2 references

DOI.org query endpoint

https://doi.org/10.1016%2FS1201-9712%2807%2960016-2

25 May 2017

19 April 2018

1 reference

19 April 2018